Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy - ISAR-CAUTION.
In conclusion, tapered discontinuation of chronic clopidogrel therapy is not superior to abrupt discontinuation regarding the primary endpoint in this study. However, the results must be interpreted in view of the premature termination of the trial and low event rates. PMID: 24633406 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 13, 2014 Category: Hematology Authors: Fiedler KA, Mehilli J, Kufner S, Schlichting A, Ibrahim T, Sibbing D, Ott I, Schunkert H, Laugwitz KL, Kastrati A, Schulz S Tags: Thromb Haemost Source Type: research

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-AF study.
CONCLUSION: If anything, despite its early termination the idrabiotaparinux regimen studied suggested a comparable efficacy to dose-adjusted warfarin, with a lower bleeding risk. This article is protected by copyright. All rights reserved. PMID: 24597472 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE Tags: J Thromb Haemost Source Type: research

Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Abstract Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported. In the absence of head to head trials directly comparing these NOACs against each other, we compared the efficacy and safety of edoxaban to other agents by an indirect comparison analysis. We performed an indirect comparison analysis of edoxaban (2 dose strategies) against apixaban (1 dose), dabigatran etexilate (2 doses) and rivaroxaban (1 dose), for their relative efficacy and safety against ea...
Source: Thrombosis and Haemostasis - February 28, 2014 Category: Hematology Authors: Skjøth F, Larsen TB, Rasmussen LH, Lip GY Tags: Thromb Haemost Source Type: research

Stroke prevention in atrial fibrillation: An Asian perspective.
Abstract Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. In 2050, it is estimated that there will be 72 million AF patients in Asia, accounting for almost 2.9 million patients suffering from AF-associated stroke. Asian AF patients share similar risk factor profiles as non-Asians, except that more Asians have a history of previous stroke. Clinical challenges are evident in the field of stroke prevention in AF, amongst Asians. Existing stroke and bleeding risk scores have not been well-validated in Asians. Asians are prone to bleeding when treated with warfarin, and the optimal internationa...
Source: Thrombosis and Haemostasis - February 6, 2014 Category: Hematology Authors: Chiang CE, Wang KL, Lip GY Tags: Thromb Haemost Source Type: research

Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation.
PMID: 24477628 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 30, 2014 Category: Hematology Authors: Lane DA, Lip GY Tags: Thromb Haemost Source Type: research

New oral anticoagulant agents - general features and outcomes in subsets of patients.
Abstract During the past four years the phase III trials on stroke prophylaxis in atrial fibrillation and in treatment of venous thromboembolism have been completed for four new oral anticoagulants - dabigatran, apixaban, edoxaban and rivaroxaban. The studies have revealed advantages in terms of a reduced risk of bleeding, most importantly of intracranial bleeding. These anticoagulants also have favourable pharmacokinetics, eliminating the need for routine laboratory monitoring and dose adjustments. There are, however, some differences between the drugs in certain subsets of patients, according to patient characte...
Source: Thrombosis and Haemostasis - January 23, 2014 Category: Hematology Authors: Schulman S Tags: Thromb Haemost Source Type: research

Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project.
In conclusion, composite risk scores did not significantly improve risk prediction of endpoints in patients with NVAF, regardless of how endpoints were defined. This would support individualised prediction of IS/TE and bleeding separately using different separate risk prediction tools, and not the use of composite scores or endpoints for everyday 'real world' clinical practice, to guide decisions on thromboprophylaxis. PMID: 24452108 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 23, 2014 Category: Hematology Authors: Banerjee A, Fauchier L, Bernard-Brunet A, Clementy N, Lip GY Tags: Thromb Haemost Source Type: research

Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation.
In conclusion, there was a substantial amount of inter-patient variability, and often extreme differences in opinion regarding tolerance of bleeding risk in the context of stroke prevention in atrial fibrillation. These findings highlight the importance of considering patient preferences when deciding on SPAF therapy. PMID: 24337399 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 12, 2013 Category: Hematology Authors: Lahaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D, Francis K Tags: Thromb Haemost Source Type: research

Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
In conclusion, this post-hoc simulation of dabigatran usage based on RE-LY trial dataset indicates that "EU label simulated dabigatran treatment" may be associated with superior efficacy and safety compared to warfarin, and are in support of the EU label and the 2012 European Society of Cardiology AF guideline recommendations. Thus, adherence to European label/guideline use results in a clinically relevant benefit for dabigatran over warfarin, for both efficacy and safety. PMID: 24326736 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2013 Category: Hematology Authors: Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S Tags: Thromb Haemost Source Type: research

Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
Abstract This review article discusses the following, as yet unanswered, questions and research priorities to optimise patient management and stroke prevention in atrial fibrillation with the new direct oral anticoagulants (NOACs): 1. In patients prescribed a NOAC, can the anticoagulant effects or plasma concentrations of the NOACs be measured rapidly and reliably and, if so, can "cut-off points" between which anticoagulation is therapeutic (i.e. the "therapeutic range") be defined? 2. In patients who are taking a NOAC and bleeding (e.g. intracerebral haemorrhage), can the anticoagulant effects of the direct NOACs...
Source: Thrombosis and Haemostasis - November 28, 2013 Category: Hematology Authors: Hankey GJ Tags: Thromb Haemost Source Type: research

Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
In conclusion, in AF patients AF, VKA cessation is independently associated with mortality stroke and cardiovascular events. Specifically, VKA cessation independently increased the risk of stroke, even after adjusting for CHA2DS2-VASc score. TTR was an independent risk factor for major bleeding following initiation of VKA therapy. PMID: 24096615 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 7, 2013 Category: Hematology Authors: Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GY Tags: Thromb Haemost Source Type: research

Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial.
In conclusion, the HAS-BLED score demonstrated significant discriminatory performance for "any clinically relevant bleeding" in anticoagulated patients with AF, whilst the CHADS2 and CHA2DS2-VASc scores did not. Bleeding risk assessment should be made using a specific bleeding risk score such as HAS-BLED, and the stroke risk scores such as CHADS2 or CHA2DS2-VASc scores should not be used. PMID: 24048467 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 19, 2013 Category: Hematology Authors: Apostolakis S, Lane DA, Buller H, Lip GY Tags: Thromb Haemost Source Type: research

Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation.
In conclusion, preventing patients with cardiovascular disease from discontinuing ASA could result in substantial clinical and economic gains. PMID: 24008261 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 5, 2013 Category: Hematology Authors: Cea Soriano L, Garcia Rodriguez L, Bueno H, Lanas A Tags: Thromb Haemost Source Type: research

Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation.
In conclusion, in patients with AF and high thromboembolic risk after stent implantation, use of OAC was independently associated with decreased risk of subsequent death/stroke/systemic TE, suggesting that OAC should be systematically used in this patient population. PMID: 23846210 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 11, 2013 Category: Hematology Authors: Bernard A, Fauchier L, Pellegrin C, Clementy N, Saint Etienne C, Banerjee A, Naudin D, Angoulvant D Tags: Thromb Haemost Source Type: research